Pathophysiology of advanced glycation end-products in renal failure

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 5, 1996, Pages 27-30

  Miyata, T ^a   Iida, Y ^a   Horie, K ^a   Cai, Z ^a   Sugiyama, S ^a   Maeda, K ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Pathophysiology; Renal failure; 2 microglobulin

Indexed keywords

AMYLOID; BETA 2 MICROGLOBULIN; SUGAR;

AMYLOIDOSIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; GLYCATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MACROPHAGE; MOLECULAR INTERACTION; MONOCYTE; OSTEOBLAST; OSTEOCLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRUCTURE ACTIVITY RELATION;

EID: 0030499861     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp5.27     Document Type: Conference Paper

References (23)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
2. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1990; 325: 836-842
3. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-5138
4. Papanastasiou P, Grass L, Rodela H et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216-222
5. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264: 21597-21602
6. Baynes JW. Perspectives in diabetes: role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412
7. Odetti P, Forgarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-159
8. Miyata T, Taneda S, Kawai R et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin forming amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA in press
9. Hricik DE, Schulak JA, Sell DR, Fogarty JF, Monnier VM. Effect of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993; 43: 398-403
10. Miyata T, Ueda Y, Iida Y et al. Accumulation of albumin-linked and freee-form pentoside in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentoside. J Am Soc Nephrol in press
11. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1998; 240: 1546-1548
12. Schmidt AM, Yon SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 92: 2155-2168
13. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sd USA 1994; 91: 9441-9445
14. Miyata T, Oda O, Inagi R et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1252
15. Miyata T, Inagi R, Iida Y et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 1994; 93: 521-528
16. Miyata T, Inagi R, Wada Y et al. Glycation of human β2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry 1994; 33: 12215-12221
17. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K. β2-Microglobulm modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 1994; 201: 1235-1241
18. Miyata T, Iida Y, Ueda Y et al. Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end products. Kidney Int 1996; 49: 538-550
19. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41: 1416-1429
20. Miyata T, Kawai R, Taneda S et al. Identification of the native structures for advanced glycation end products in β2-microglobulin forming amyloid fibrils in patients with dialysis-related amyloidosis (abstract). J Am Soc Nephrol 1995; 6: 552
21. Ohashi K, Hara M, Kawai R et al. Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 1992; 41: 1646-1652
22. Miyata T, Notoya, K, Iida Y, Taketomi S, Tsuda M, Maeda K. β2-Microglobulin modified with advanced glycation end product enhances bone resorption of osteoclasts: role in the pathogenesis of dialysis-related amyloidosis (abstract). J Am Soc Nephrol 1995; 6:552
23. Iida Y, Miyata T, Maeda K, Hori O, Stern D, Schmidt AM. Monocyte/macrophge interaction of nonenzymatically glycated β2-microglobulin is mediated by the receptor for advanced glycation end products: role in the pathogenesis of dialysis-related amyloidosis (abstract). J Am Soc Nephrol 1995; 6: 536